Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 1.70
CHRS's Cash-to-Debt is ranked lower than
78% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. CHRS: 1.70 )
Ranked among companies with meaningful Cash-to-Debt only.
CHRS' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.24  Med: N/A Max: No Debt
Current: 1.7
Equity-to-Asset 0.34
CHRS's Equity-to-Asset is ranked lower than
89% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CHRS: 0.34 )
Ranked among companies with meaningful Equity-to-Asset only.
CHRS' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.05  Med: 0.14 Max: 0.39
Current: 0.34
-2.05
0.39
Piotroski F-Score: 4
Altman Z-Score: 0.36
Beneish M-Score: 2.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -69.70
CHRS's Operating Margin % is ranked higher than
54% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. CHRS: -69.70 )
Ranked among companies with meaningful Operating Margin % only.
CHRS' s Operating Margin % Range Over the Past 10 Years
Min: -2028.33  Med: -729.23 Max: -60.98
Current: -69.7
-2028.33
-60.98
Net Margin % -76.85
CHRS's Net Margin % is ranked higher than
52% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. CHRS: -76.85 )
Ranked among companies with meaningful Net Margin % only.
CHRS' s Net Margin % Range Over the Past 10 Years
Min: -1949.65  Med: -743.18 Max: -66.98
Current: -76.85
-1949.65
-66.98
ROE % -14620.08
CHRS's ROE % is ranked lower than
99.99% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. CHRS: -14620.08 )
Ranked among companies with meaningful ROE % only.
CHRS' s ROE % Range Over the Past 10 Years
Min: -14620.08  Med: -1257.68 Max: -736.9
Current: -14620.08
-14620.08
-736.9
ROA % -63.55
CHRS's ROA % is ranked lower than
73% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. CHRS: -63.55 )
Ranked among companies with meaningful ROA % only.
CHRS' s ROA % Range Over the Past 10 Years
Min: -145  Med: -111.74 Max: -63.55
Current: -63.55
-145
-63.55
ROC (Joel Greenblatt) % -1128.39
CHRS's ROC (Joel Greenblatt) % is ranked lower than
64% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. CHRS: -1128.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CHRS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2990.18  Med: -2679.87 Max: -1126.23
Current: -1128.39
-2990.18
-1126.23
GuruFocus has detected 2 Warning Signs with Coherus BioSciences Inc $CHRS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CHRS's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

CHRS Guru Trades in Q2 2016

Paul Tudor Jones 11,300 sh (New)
Jim Simons 94,500 sh (New)
Steven Cohen 37,500 sh (-71.42%)
» More
Q3 2016

CHRS Guru Trades in Q3 2016

Joel Greenblatt 17,363 sh (New)
Steven Cohen Sold Out
Jim Simons Sold Out
Paul Tudor Jones 10,670 sh (-5.58%)
» More
Q4 2016

CHRS Guru Trades in Q4 2016

Steven Cohen 601,034 sh (New)
Joel Greenblatt 32,982 sh (+89.96%)
Paul Tudor Jones 14,396 sh (+34.92%)
» More
Q1 2017

CHRS Guru Trades in Q1 2017

Jim Simons 113,200 sh (New)
Paul Tudor Jones 23,223 sh (+61.32%)
Joel Greenblatt 36,380 sh (+10.30%)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CHRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 2836
Compare:NAS:DERM, NAS:FOLD, NAS:LOXO, OTCPK:GNFTF, NYSE:EBS, NAS:INSM, NAS:EPZM, NAS:XNCR, OTCPK:PFSCF, NAS:INVA, NAS:GBT, OTCPK:PHMMF, NAS:XLRN, NAS:RGEN, NAS:CORT, NAS:AIMT, NAS:FWP, NAS:ZIOP, NAS:INSY, NAS:AKAO » details
Headquarter Location:USA
Coherus BioSciences Inc is a biotechnology company that develops biosimilar therapeutics. The company seeks to ensure successful drug development and manufacturing under very aggressive timelines.

Coherus BioSciences is a biotechnology company that develops biosimilar therapeutics. The company focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Coherus' commercialization partnerships include global pharmaceutical companies in Europe, Asia, and Latin America. The company seeks to ensure successful drug development and manufacturing under very aggressive timelines. Coherus generates the vast majority of its revenue in the United States.

Top Ranked Articles about Coherus BioSciences Inc

AbbVie's Humira Loses Patent in Coherus’ Petitions Why this lost patent will not hit Humira's sales
It seems that the decision of the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board to rule “in favor of Coherus’ petitions for Inter Partes Review (“IPR”) of AbbVie’s U.S. Patent 8,889,135 (the 135 Patent)” as reported by Coherus Biosciences (NASDAQ:CHRS) through its Web site, is not weighing so much on AbbVie Inc. (NYSE:ABBV) whose shares have – in contrast – resumed their uptrending and are $65.40 each, up 3 cents or plus 6% from the previous trading day. Read more...
Coherus BioSciences Reports First Quarter 2017 Corporate Highlights and Financial Results
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in May
Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar
Coherus BioSciences to Report First Quarter 2017 Financial Results on May 8th
Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development

REDWOOD CITY, Calif., March 27, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced the appointment of Erik Wiberg as Executive Vice President of Corporate Development.  Mr. Wiberg joins Coherus with more than 30 years of experience, including more than 18 years in various business development and corporate finance roles at biopharmaceutical companies, and 13 years in healthcare investment banking and equity research.  In this position, Mr. Wiberg will be responsible for product licensing, corporate strategy, as well as M&A.
“We are very gratified to have a corporate development professional of Mr. Wiberg’s caliber choose to join the Coherus team,” said Denny Lanfear, President and Chief Executive Officer of Coherus. “2017 is a transformational year for Coherus, as we prepare our first product approval. Erik’s proven track record of execution within corporate development will be critical to effectively achieving our business objectives.” Mr. Wiberg has extensive experience in corporate development, completing numerous out-licensing, in-licensing, merger and acquisition, and financing transactions and research & development collaborations that achieved corporate priorities and created significant value for shareholders at ALZA Corporation, Johnson & Johnson, Anacor Pharmaceuticals, Inc., and Catalyst Biosciences, Inc.  Erik was most recently Senior Vice President, Strategy and Corporate Development at Anacor Pharmaceuticals, Inc. a company acquired by Pfizer in 2016 for $5.2 billion.  He has also held leadership positions in corporate strategy, new product planning and portfolio management.  Erik earned his dual degree in business and engineering from University of Pennsylvania, where he attended the Wharton School of Business and earned his Bachelor of Science in Economics, dual major in Finance and Accounting, and the School of Engineering and Applied Science where he earned his Bachelor of Applied Science with a major in Computer Science Engineering. About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com. Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Coherus’ plans, expectations, goals, objectives, strategies, product pipeline, clinical studies, product development, and the potential benefits of its products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding our ability to effectively achieve our business objectives. Such forward-looking statements involve substantial risks and uncertainties that relate to future events and the actual results could differ significantly from those expressed or implied by the forward-looking statements. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, please refer to the Company’s Annual Report on Form 10-K filed with the SEC on March 13, 2016 and its subsequent periodic reports filed with the SEC.
CONTACT:
Patrick O’Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
1 (650) 649-3527

Read more...
Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Results

REDWOOD CITY, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today reviewed corporate events and reported financial results for the fourth quarter and full year 2016.
Corporate Highlights for the Fourth Quarter 2016 Include:
Oncology therapeutic franchise: CHS-1701 (pegfilgrastim (Neulasta®) biosimilar candidate)
- Announced that the U.S. FDA has accepted the filing of 351(k) Biologics License Application (BLA) for CHS-1701. The first FDA submission and acceptance for Coherus.
- Announced acceptance of Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for CHS-1701. This is the first EMA submission and acceptance for Coherus. Immunology (anti-TNF) therapeutic franchise: CHS-1420 (adalimumab (Humira®) biosimilar candidate)
- Received decision from the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office denying institution of petition for Inter Partes Review (IPR) of AbbVie’s U.S. Patent 9,114,166 (the “’166 Patent”) related to AbbVie’s HUMIRA (adalimumab) formulation.   CHS-0214 (etanercept (Enbrel®) biosimilar candidate)
- Announced results from two pharmacokinetic (PK) studies involving CHS-0214. The CHS-0214-06 trial compared CHS-0214 vs. European Union (EU) Enbrel and achieved the primary PK BE endpoint, as the 90% confidence intervals for the geometric mean ratio for the two groups was within 80% to 125% for all PK parameters. The CHS-0214-07 trial provided additional relative bioavailability data for CHS-0214.      Financial Highlights for the Fourth Quarter 2016 include: On October 28, 2016, Coherus entered into a Sales Agreement with Cowen and Company, LLC to sell shares of the Company’s common stock with aggregate gross sales proceeds of up to $100,000,000, from time to time, through an “at the market” equity offering program under which Cowen will act as sales agent.  During the fourth quarter of 2016 and in January 2017, Coherus issued 2.2 million shares and raised $60.8 million in gross proceeds under this program at an average price per share of $28.10.  Fourth Quarter and Full Year 2016 Financial Results: Total revenue for the fourth quarter of 2016 was $844 thousand, as compared to $10.2 million in the fourth quarter of 2015.  Total revenue for the fiscal year 2016 was $190.1 million, as compared to $30.0 million in 2015.  The increase over the same period in 2015 was due to increased recognition of collaboration revenue as a result of regaining the full development and commercial rights for CHS-0214 from Shire in Europe, Canada, Brazil, the Middle East and certain other territories.
 Research and development (R&D) expenses for the fourth quarter of 2016 were $59.0 million compared to $51.4 million for the same period in 2015.  R&D expenses for the fiscal year 2016 were $254.4 million, as compared to $213.1 million for the same period in 2015.  The increase in R&D expenses in the fourth quarter over the same period in 2015 was mainly due to analytical studies for early stage programs and CHS-0214 programs, on-going CHS-1420 PK and Phase 3 trials, offset by completion of the CHS-1701 BLA-enabling and CHS-0214 Phase 3 clinical program.  The increase in R&D expenses in the fiscal year ended 2016 over the same period in 2015 was mainly attributable to proceeding with clinical activities associated with a Phase 3 clinical study in psoriasis for CHS-1420, advances in other product candidates,  and hiring additional personnel to support both late-development and early-stage activities, partially offset by a decrease in costs related to BLA-enabling studies for CHS-1701 and a decrease in costs associated with the CHS-0214 Phase 3 trials that were completed in the first half of 2016.
 General and administrative (G&A) expenses for the fourth quarter of 2016 were $15.3 million, compared to $11.0 million for the same period in 2015. G&A expenses for the fiscal year 2016 were $51.6 million, as compared to $36.0 million for the same period in 2015.  Changes in G&A expenses were mainly attributable to hiring employees to support pre-commercial and accounting activities, costs associated with stock options granted since the third quarter of 2015 and legal fees to support the intellectual property strategy. 
 Net loss attributable to Coherus for the fourth quarter of 2016 was ($75.9) million, or ($1.71) per share, compared to a net loss of ($52.4) million, or ($1.35) per share, for the same period in 2015. Net loss attributable to Coherus for 2016 was ($127.3) million, or ($3.04) per share, compared to a net loss of ($223.3) million, or ($6.01) per share, for 2015.
 Cash and cash equivalents totaled $124.9 million as of December 31, 2016, compared to $159.7 million as of September 30, 2016.  Coherus raised an additional $120.3 million in net proceeds from a follow-on equity offering in February and March 2017. 2017 Guidance:
Oncology therapeutic franchise: CHS-1701 (pegfilgrastim biosimilar)
- U.S. marketing approval, anticipated on the BSUFA date of June 9, 2017.
- European Marketing approval anticipated in the fourth quarter of 2017.
- Continue commercial partnering discussions for certain ex-U.S. territories, targeting agreement in place in the first half of 2017. Immunology (anti-TNF) therapeutic franchise: CHS-1420 (adalimumab biosimilar)
- Anticipate a 351(k) BLA submission in the U.S. in the second quarter of 2017.
- Anticipate a decision from the Patent Trial and Appeal Board of the U.S. Patent and Trademark office on the Inter Partes Review of AbbVie’s U.S. Patent 8,889,135 (“the ‘135 Patent”)  by May 17, 2017.
- Continue to advance intellectual property strategies, supporting potential 2018 launch.
- Initiate a PK study on formulation not impacted by AbbVie US Patent 9,114,166 (‘166) in the second-half of 2017, if the ‘135 Patent is invalidated by the Patent Trial and Appeal Board.
- Institution decision on four petitions for Inter Partes Review (IPR) of AbbVie’s U.S. Patent 9,085,619 in the third quarter of 2017.CHS-0214 (etanercept biosimilar)
- Anticipate filing of Marketing Authorization Application (MAA) in the second half of 2017.Partnering discussions for the immunology (anti-TNF) therapeutic franchise are underway, targeting agreement in place in the first half of 2017, subject to a favorable ‘135 IPR decision. Other: Complete additional animal studies on CHS-131 to further validate its mechanism of action, pursuant to a licensing agreement in the second half of 2017.Management anticipates prioritizing use of cash towards CHS-1701 commercialization activities. Conference Call Information
When: Monday, March 13, 2017 at 4:30 p.m. ET
Dial-in: (844) 452-6826 (toll free) or (765) 507-2587 (International)
Conference ID: 66529524
Webcast:  http://investors.coherus.com
Please join the conference call at least 10 minutes early to register.  The webcast will be archived on the Coherus website. About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com. Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Coherus’ plans, potential opportunities, expectations, projections, goals, objectives, milestones, strategies, product pipeline, clinical studies, product development, release of data and the potential benefits of its products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including Coherus’ ability to complete a partnering agreement and receive MAA acceptance for CHS-1701, receive MAA acceptance for CHS-0214, initiate a bioavailability study for CHS-0214 and  receive BLA acceptance for CHS-1420, complete a partnering agreement for its immunology (anti-TNF) therapeutic franchise, to complete additional studies for and partner CHS-131, to prioritize its use of cash towards CHS-1701 commercialization activities, and to successfully defend against the trade secret and related allegations made by Amgen in the lawsuit filed against Coherus and other parties with respect to CHS-1701 and to be able to launch that product on a timely basis assuming approval of our New Drug Application by the U.S. Food and Drug Administration. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of our regulatory filings and other matters that could affect the availability or commercial potential of our biosimilar drug candidates, as well as possible patent litigation. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Annual Report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission on March 13, 2017 and its future periodic reports to be filed with the Securities and Exchange Commission. Enbrel® and Neulasta® are registered trademarks of Amgen Inc.
Humira® is a registered trademark of AbbVie Inc. Coherus BioSciences, Inc.Condensed Consolidated Statements of Operations(in thousands, except share and per share data)           Three Months Ended  Twelve Months Ended  December 31, December 31,  2016 2015 2016 2015                   (unaudited)  Revenue:        Collaboration and license revenue $214  $10,198  $189,476  $30,041 Other revenue  630   â€”   630   â€” Total revenue  844   10,198   190,106   30,041 Operating expenses:        Research and development  59,010   51,433   254,440   213,062 General and administrative  15,294   10,972   51,597   36,046 Total operating expenses  74,304   62,405   306,037   249,108                  Loss from operations  (73,460)  (52,207)  (115,931)  (219,067)Interest expense  (2,369)  â€”   (7,980)  (33)Other expense, net  (115)  (373)  (3,877)  (4,838)Net loss  (75,944)  (52,580)  (127,788)  (223,938)Net loss attributable to non-controlling interest  23   189   451   678 Net loss attributable to Coherus $(75,921) $(52,391) $(127,337) $(223,260)         Net loss per share attributable to Coherus, basic and diluted $(1.71) $(1.35) $(3.04) $(6.01)Weighted-average number of shares used in computing net loss per share attributable to Coherus, basic and diluted  44,341,121   38,935,832   41,912,300   37,122,008                     Coherus BioSciences, Inc.Condensed Consolidated Balance Sheets(in thousands)       December 31, December 31,   2016   2015       Assets     Cash and cash equivalents $  124,947 $  158,226 Other assets    53,538    54,158 Total assets $  178,485 $  212,384 Liabilities and Stockholders’ Equity (deficit)    Deferred revenue    1,561    94,959 Convertible notes    75,192   â€”  Convertible notes-related parties    25,064   â€”  Other liabilities     57,314    124,354 Total stockholders' equity (deficit)    19,354    (6,929)Total liabilities and stockholders’ equity (deficit) $  178,485 $  212,384      
CONTACT:
Patrick O’Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
1 (650) 649-3527

Read more...
Coherus Addresses Trade Secret Action Filed by Amgen

REDWOOD CITY, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced that Amgen has filed a trade secret action in California state court on March 3, 2017 alleging trade secret misappropriation and other claims against Coherus and other parties. 
“Coherus believes that this action is without merit and will defend against it vigorously,” said Denny Lanfear, President and Chief Executive Officer of Coherus. “We categorically reject the theme of Amgen’s complaint that Coherus has engaged, or is engaging, in a scheme to misappropriate trade secrets or commit other wrongdoing.  Coherus believes this lawsuit is best understood as an effort by Amgen to use baseless litigation in an effort to delay Coherus as a competitor in the pegfilgrastim market.” Mr. Lanfear also noted, “Coherus does not need Amgen’s proprietary information to compete or be successful. We are proud of Coherus’ novel clinical development strategy and novel clinical study designs that were never performed at Amgen and are not Amgen’s intellectual property.” Mr. Lanfear further noted, “We place a high value on employee integrity and Coherus has had in place significant control practices regarding both the recruitment and conduct of incoming personnel.”   Finally, Mr. Lanfear emphasized, “Coherus remains committed to the important goal of bringing much-needed biosimilar drugs to the marketplace. We are confident that we will prevail in this action and achieve our goals of increasing patient access, introducing competition and offering biosimilar products at prices competitive with and lower than those maintained by Amgen and other large pharmaceutical companies.” About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com. Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Coherus’ plans, expectations, goals, objectives, strategies, product pipeline, clinical studies, product development, and the potential benefits of its products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding our ability to successfully defend against the trade secret and related allegations made by Amgen in the lawsuit filed against Coherus and other parties with respect to our pegfilgrastim product and to be able to launch that product on a timely basis assuming approval of our New Drug Application by the U.S. Food and Drug Administration.  Such forward-looking statements involve substantial risks and uncertainties that relate to future events and the actual results could differ significantly from those expressed or implied by the forward-looking statements. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, please refer to the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 9, 2016 and its subsequent periodic reports filed with the SEC, including its Prospectus Supplement filed on February 8, 2017.
CONTACT:
Patrick O’Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
1 (650) 649-3527

Read more...
Coherus Announces CHS-1420 Pharmacokinetic Clinical Bioequivalence Study Meets Primary Endpoint

REDWOOD CITY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a clinical pharmacokinetic (PK) bioequivalence study that compared CHS-1420 to Humira in healthy subjects.  The study met the criteria for clinical PK similarity on all prospectively defined PK endpoints: maximum serum concentration (Cmax), area under the time-concentration curve from first to last time point measured (AUC-0-last), and area under the time-concentration curve from first time point extrapolated to infinity (AUC0-inf).  The 90% confidence intervals of the geometric mean ratios for all PK endpoints fell well within the bioequivalence boundaries of 80% to 125%.  Both agents were well tolerated and there were no differential safety findings observed between the two agents in this study.
CHS-1420-03 was a randomized, double-blind, parallel-group study in healthy subjects designed to assess the PK bioequivalence of CHS-1420 to that of Humira by comparing relative bioavailability after sub-cutaneous administration of a single 40 mg dose.  The safety and tolerability of CHS-1420 was also evaluated.
“Positive results from this study are an essential global regulatory requirement to demonstrate PK bioequivalence on multiple prespecified primary PK endpoints between CHS-1420 and Humira,” said Barbara Finck, M.D., Chief Medical Officer of Coherus. “We are pleased to have achieved results which we believe represent a significant reduction in development program risk.” “This is our second successful CHS-1420 PK study,” noted Denny Lanfear, President and Chief Executive Officer of Coherus. “Our ability to achieve these results gives us confidence that we can similarly complete future PK studies with modified formulations, anticipated to commence later in 2017.” About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com. Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Coherus’ plans, expectations, goals, objectives, strategies, product pipeline, clinical studies, product development, and the potential benefits of its products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding our ability to initiate and replicate a similar PK Phase 1 study with modified formulations for CHS-1420. Such forward-looking statements involve substantial risks and uncertainties that relate to future events and the actual results could differ significantly from those expressed or implied by the forward-looking statements. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, please refer to the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 9, 2016 and its subsequent periodic reports filed with the SEC, including its Prospectus Supplement filed on February 8, 2017.
CONTACT:
Patrick O’Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
1 (650) 649-3527

Read more...
Statement by Coherus CEO Regarding Biosimilars User Fees

REDWOOD CITY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced that Coherus BioSciences’ Vice President of Government Affairs, Juliana Reed testified in support of the reauthorization of the Biosimilar User Fee Program for FY2018 –FY2022 (BsUFA II) on behalf of the Biosimilars Forum at the House Energy and Commerce Committee hearing on FDA’s generic drug and biosimilar user fee programs.
Ms. Reed spoke in support of the reauthorization of BsUFA II, highlighting its importance to not only the biosimilars industry, but also to patients and the healthcare system as a whole. Denny Lanfear, President and Chief Executive Officer of Coherus BioSciences, stated: “I would like to communicate our unequivocal support of BsUFA II and emphasize how important adequate funding and support of the FDA biosimilars program is to the success of our industry and the future increased patient access and cost-savings these medicines will bring.  On behalf of Coherus BioSciences, I strongly encourage Congress to demonstrate its support of the FDA and biosimilars by reauthorizing BsUFA II in a timely manner.” You can read Ms. Reed’s full testimony by following the link below: https://energycommerce.house.gov/hearings-and-votes/hearings/examining-fda-s-generic-drug-and-biosimilar-user-fee-programs About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT:
Patrick O'Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
1 (650) 649-3527

Read more...

Ratios

vs
industry
vs
history
PB Ratio 13.29
CHRS's PB Ratio is ranked lower than
98% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CHRS: 13.29 )
Ranked among companies with meaningful PB Ratio only.
CHRS' s PB Ratio Range Over the Past 10 Years
Min: 6.35  Med: 22.05 Max: 63.17
Current: 13.29
6.35
63.17
PS Ratio 5.74
CHRS's PS Ratio is ranked higher than
68% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. CHRS: 5.74 )
Ranked among companies with meaningful PS Ratio only.
CHRS' s PS Ratio Range Over the Past 10 Years
Min: 5.21  Med: 19.52 Max: 41.41
Current: 5.74
5.21
41.41
EV-to-EBIT -7.56
CHRS's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. CHRS: -7.56 )
Ranked among companies with meaningful EV-to-EBIT only.
CHRS' s EV-to-EBIT Range Over the Past 10 Years
Min: -15.6  Med: -6.45 Max: -1.6
Current: -7.56
-15.6
-1.6
EV-to-EBITDA -7.73
CHRS's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. CHRS: -7.73 )
Ranked among companies with meaningful EV-to-EBITDA only.
CHRS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16  Med: -6.5 Max: -1.6
Current: -7.73
-16
-1.6
Current Ratio 4.40
CHRS's Current Ratio is ranked lower than
64% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. CHRS: 4.40 )
Ranked among companies with meaningful Current Ratio only.
CHRS' s Current Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.67 Max: 4.4
Current: 4.4
0.85
4.4
Quick Ratio 4.40
CHRS's Quick Ratio is ranked lower than
60% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CHRS: 4.40 )
Ranked among companies with meaningful Quick Ratio only.
CHRS' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.67 Max: 4.4
Current: 4.4
0.85
4.4
Days Sales Outstanding 0.05
CHRS's Days Sales Outstanding is ranked higher than
94% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. CHRS: 0.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
CHRS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.05  Med: 28.36 Max: 36.88
Current: 0.05
0.05
36.88

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 40.50
CHRS's Price-to-Net-Cash is ranked lower than
99.99% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. CHRS: 40.50 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CHRS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 19.46 Max: 43.7
Current: 40.5
0
43.7
Price-to-Net-Current-Asset-Value 17.61
CHRS's Price-to-Net-Current-Asset-Value is ranked lower than
99% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. CHRS: 17.61 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CHRS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 31.9 Max: 351.88
Current: 17.61
0
351.88
Price-to-Tangible-Book 13.87
CHRS's Price-to-Tangible-Book is ranked lower than
97% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. CHRS: 13.87 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CHRS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 8.58  Med: 25.4 Max: 76.08
Current: 13.87
8.58
76.08
Price-to-Median-PS-Value 0.29
CHRS's Price-to-Median-PS-Value is ranked higher than
87% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CHRS: 0.29 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CHRS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.98 Max: 1.84
Current: 0.29
0
1.84
Earnings Yield (Greenblatt) % -13.22
CHRS's Earnings Yield (Greenblatt) % is ranked lower than
62% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. CHRS: -13.22 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CHRS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -13.5  Med: 0 Max: 1088.85
Current: -13.22
-13.5
1088.85

More Statistics

Revenue (TTM) (Mil) $177.9
EPS (TTM) $ -3.38
Short Percentage of Float14.32%
52-Week Range $14.00 - 31.98
Shares Outstanding (Mil)51.29

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 47 68 312
EPS ($) -4.99 -3.20 1.22
EPS without NRI ($) -4.99 -3.20 1.22
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CHRS

Headlines

Articles On GuruFocus.com
AbbVie's Humira Loses Patent in Coherus’ Petitions May 18 2017 
Coherus BioSciences Reports First Quarter 2017 Corporate Highlights and Financial Results May 08 2017 
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in May May 01 2017 
Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar Apr 25 2017 
Coherus BioSciences to Report First Quarter 2017 Financial Results on May 8th Apr 24 2017 
Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development Mar 27 2017 
Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Res Mar 13 2017 
Coherus Addresses Trade Secret Action Filed by Amgen Mar 06 2017 
Coherus Announces CHS-1420 Pharmacokinetic Clinical Bioequivalence Study Meets Primary Endpoint Mar 02 2017 
Statement by Coherus CEO Regarding Biosimilars User Fees Mar 02 2017 

More From Other Websites
[$$] AbbVie: It's the Pipeline, Not the Coherus Ruling May 18 2017
AbbVie Down on Humira Patent Loss: Is More Damage in Store? May 18 2017
AbbVie Loses Key Humira Patent In Battle With Small-Cap Biotech May 17 2017
Why This Humira Patent Loss Might Not Be What You Think May 17 2017
AbbVie Stock Lower on Humira Patent Ruling May 17 2017
Coherus BioSciences Prevails in ‘135 IPR Decision May 16 2017
Edited Transcript of CHRS earnings conference call or presentation 8-May-17 8:30pm GMT May 13 2017
Coherus BioSciences, Inc. – Value Analysis (NASDAQ:CHRS) : May 12, 2017 May 12 2017
Are Options Traders Betting on a Big Move in COHERUS BIOSCIENCES (CHRS) Stock? May 12 2017
Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : May 11,... May 11 2017
Coherus BioSciences reports 1Q loss May 08 2017
Coherus BioSciences Reports First Quarter 2017 Corporate Highlights and Financial Results May 08 2017
Investor Network: Coherus BioSciences, Inc. to Host Earnings Call May 08 2017
The Prospects For CHS-3351, Coherus' Most Underappreciated Asset May 05 2017
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in May May 01 2017
ETFs with exposure to Coherus BioSciences, Inc. : April 25, 2017 Apr 25 2017
Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar Apr 25 2017
Coherus BioSciences to Report First Quarter 2017 Financial Results on May 8th Apr 24 2017
Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development Mar 27 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)